Abstract
Get full access to this article
View all access options for this article.
References
1.
Arthurs
JR
Nordan
LM
Hultgren
BH
, et al . Patients seeking stem cell therapies—a prospective qualitative analysis from a Regenerative Medicine Consult Service . NPJ Regen Med . 2022 ;7 (1 ):20 .
2.
Eliasberg
CD
Nemirov
DA
Mandelbaum
BR
, et al . Complications following biologic therapeutic injections: a multicenter case series . Arthroscopy . 2021 ;37 (8 ):2600 -2605 .
3.
Gellad
ZF
Lyles
KW.
Direct-to-consumer advertising of pharmaceuticals . Am J Med . 2007 ;120 (6 ):475 -480 .
4.
Rosenthal
MB
Berndt
ER
Donohue
JM
Epstein
AM
Frank
RG
; Kaiser Family Foundation. Impact of direct-to-consumer advertising on prescription drug spending . Published June 10, 2003. https://www.kff.org/wp-content/uploads/2003/06/6084-impact-of-direct-to-consumer-advertising-on-prescription-drug-spending-summary-of-findings.pdf
5.
Schaffer
JJ
Bozic
KJ
Dorr
LD
Miller
DA
Nepola
JV.
Direct-to-consumer marketing in orthopaedic surgery: boon or boondoggle? J Bone Joint Surg Am . 2008 ;90 (11 ):2534 -2543 .
6.
Schwartz
LM
Woloshin
S.
Medical marketing in the United States, 1997-2016 . JAMA . 2019 ;321 (1 ):80 -96 .
7.State of Georgia Office of the Attorney General . Carr, FTC hold companies accountable for deceptive claims regarding stem cell therapy . Published August 17, 2021. https://law.georgia.gov/press-releases/2021-08-17/carr-ftc-hold-companies-accountable-deceptive-claims-regarding-stem-cell
8.US Food and Drug Administration Statement . FDA warns US stem cell clinic of significant deviations . Published August 28, 2017. https://www.fda.gov/news-events/press-announcements/fda-warns-us-stem-cell-clinic-significant-deviations
9.US Food and Drug Administration . Statement from FDA commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapy and regenerative medicine . Published August 28, 2017. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fdas-new-policy-steps-and-enforcement-efforts-ensure